Analysis: Venus Remedies Limited

NSE:VENUSREM Pharmaceuticals - I V Fluids Market cap: ₹2.3K cr

Growth thesis

Venus Remedies Ltd is a specialized Indian manufacturer of intravenous (IV) fluids, catering primarily to hospitals and healthcare providers. Its core business revolves around sterile injectables, a critical component of hospital care with stable demand. Growth is expected to stem from expanding healthcare infrastructure in emerging markets and potential margin expansion through scale. Over the next 2-3 years, the company could benefit from secular demand for hospital-grade IV solutions and strategic product diversification. Key execution risks include regulatory scrutiny and pricing pressures in the generic pharmaceutical sector.

Research report

companyname: Venus Remedies Limited ticker: VENUSREM sector: Pharmaceuticals / Critical Care & AMR-focused Generics Venus Remedies is a research-led injectable generic and speciality pharmaceutical company incorporated in 1989 and headquartered in Panchkula, Haryana. It manufactures critical-care formulations across antimicrobial resistance, oncology, neurology, pain management, anticoagulants, herbal therapeutics and disinfectants. In FY25 it reported total revenue of ₹647.89 crore, EBITDA of ...

Read the full report →
RS rating: 87 Stage: Stage 2

Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Venus Remedies Limited and 4,900+ companies.

Sign in
5-day free pass. No card required.